WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.
Also called NCT04551456
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT04551456
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT04551456. Randomized; double masking; primary purpose treatment. Start 2020-11-30 (anticipated); primary completion 2021-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease
- Acronym
- WANICHD
- Condition
- Coronary Artery Disease
- Intervention (Biological)
- Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS
- Lead sponsor
- Navy General Hospital, Beijing
- Collaborator
- Chinese PLA General Hospital
- Collaborator
- Peking University Third Hospital
- Collaborator
- Peking Union Medical College Hospital
- Collaborator
- Xijing Hospital
Record details
- Record id
cardio:ct-nct04551456- Content hash
c3c2b6016bae07562b3237ad0fe147d848b6457bada83c1ebb216da20fd8081c